JPH0526506B2 - - Google Patents

Info

Publication number

JPH0526506B2

JPH0526506B2 JP59012599A JP1259984A JPH0526506B2 JP H0526506 B2 JPH0526506 B2 JP H0526506B2 JP 59012599 A JP59012599 A JP 59012599A JP 1259984 A JP1259984 A JP 1259984A JP H0526506 B2 JPH0526506 B2 JP H0526506B2

Authority

JP

Japan

Prior art keywords

blood

plasma

pump

bag

conduit

Prior art date

1984-01-26

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Expired - Lifetime

Links

• Espacenet
• Global Dossier
• Discuss

• 210000004369 blood Anatomy 0.000 claims description 198
• 239000008280 blood Substances 0.000 claims description 198
• 230000017531 blood circulation Effects 0.000 claims description 5
• 210000003462 vein Anatomy 0.000 claims description 5
• 238000010241 blood sampling Methods 0.000 claims description 2
• 210000002381 plasma Anatomy 0.000 description 101
• 239000003146 anticoagulant agent Substances 0.000 description 18
• 229940127219 anticoagulant drug Drugs 0.000 description 18
• 238000001802 infusion Methods 0.000 description 13
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
• 238000002474 experimental method Methods 0.000 description 8
• 238000010586 diagram Methods 0.000 description 7
• 238000000926 separation method Methods 0.000 description 7
• 239000012528 membrane Substances 0.000 description 6
• 230000000052 comparative effect Effects 0.000 description 5
• 238000005534 hematocrit Methods 0.000 description 5
• 239000003978 infusion fluid Substances 0.000 description 5
• 238000000034 method Methods 0.000 description 5
• 239000000243 solution Substances 0.000 description 5
• BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 4
• 210000003743 erythrocyte Anatomy 0.000 description 3
• 210000003734 kidney Anatomy 0.000 description 3
• 238000002360 preparation method Methods 0.000 description 3
• 210000001772 blood platelet Anatomy 0.000 description 2
• 210000001124 body fluid Anatomy 0.000 description 2
• 239000010839 body fluid Substances 0.000 description 2
• 238000007865 diluting Methods 0.000 description 2
• 238000010790 dilution Methods 0.000 description 2
• 239000012895 dilution Substances 0.000 description 2
• 238000011049 filling Methods 0.000 description 2
• 210000000265 leukocyte Anatomy 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 239000002504 physiological saline solution Substances 0.000 description 2
• 229920003023 plastic Polymers 0.000 description 2
• 239000004033 plastic Substances 0.000 description 2
• 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
• -1 polyethylene Polymers 0.000 description 2
• 239000004926 polymethyl methacrylate Substances 0.000 description 2
• 229920001296 polysiloxane Polymers 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 102000004169 proteins and genes Human genes 0.000 description 2
• 108090000623 proteins and genes Proteins 0.000 description 2
• 238000004904 shortening Methods 0.000 description 2
• 238000005303 weighing Methods 0.000 description 2
• KXNPVXPOPUZYGB-IOVMHBDKSA-N (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]-1-oxopentyl]-4-methyl-2-piperidinecarboxylic acid Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NCC(C)C2 KXNPVXPOPUZYGB-IOVMHBDKSA-N 0.000 description 1
• 102100033806 Alpha-protein kinase 3 Human genes 0.000 description 1
• 101710082399 Alpha-protein kinase 3 Proteins 0.000 description 1
• 206010002091 Anaesthesia Diseases 0.000 description 1
• 102000004506 Blood Proteins Human genes 0.000 description 1
• 108010017384 Blood Proteins Proteins 0.000 description 1
• BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 206010018910 Haemolysis Diseases 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• 239000004743 Polypropylene Substances 0.000 description 1
• 239000004372 Polyvinyl alcohol Substances 0.000 description 1
• 230000037005 anaesthesia Effects 0.000 description 1
• 230000004872 arterial blood pressure Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 230000008081 blood perfusion Effects 0.000 description 1
• 229910001424 calcium ion Inorganic materials 0.000 description 1
• 229920002301 cellulose acetate Polymers 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 238000004140 cleaning Methods 0.000 description 1
• 238000011109 contamination Methods 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 230000000694 effects Effects 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 210000003191 femoral vein Anatomy 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• DNTNDFLIKUKKOC-UHFFFAOYSA-N gabexate methanesulfonate Chemical compound CS([O-])(=O)=O.CCOC(=O)C1=CC=C(OC(=O)CCCCCN=C(N)[NH3+])C=C1 DNTNDFLIKUKKOC-UHFFFAOYSA-N 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 230000008588 hemolysis Effects 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 239000012510 hollow fiber Substances 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 239000000203 mixture Substances 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• MQQNFDZXWVTQEH-UHFFFAOYSA-N nafamostat Chemical compound C1=CC(N=C(N)N)=CC=C1C(=O)OC1=CC=C(C=C(C=C2)C(N)=N)C2=C1 MQQNFDZXWVTQEH-UHFFFAOYSA-N 0.000 description 1
• 229950009865 nafamostat Drugs 0.000 description 1
• 230000035699 permeability Effects 0.000 description 1
• 239000004417 polycarbonate Substances 0.000 description 1
• 229920000515 polycarbonate Polymers 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 229920000098 polyolefin Polymers 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• 229920002451 polyvinyl alcohol Polymers 0.000 description 1
• 229920000915 polyvinyl chloride Polymers 0.000 description 1
• 239000004800 polyvinyl chloride Substances 0.000 description 1
• 150000003180 prostaglandins Chemical class 0.000 description 1
• 239000002994 raw material Substances 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 229910000162 sodium phosphate Inorganic materials 0.000 description 1
• 230000001225 therapeutic effect Effects 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1